Innovative Interventional Products
DLong MedTech is developing purpose-built vascular intervention technologies for pulmonary and coronary disease, including pulmonary artery balloon products, drug-coated balloon platforms, and vascular interventional training solutions.
DLong’s Solution of Stent-Free Therapy for Coronary Disease
Stent-Free Coronary Drug-Coated Balloon for Small Vessels
An FDA Breakthrough Device-designated coronary drug-coated balloon (DCB) catheter being developed as a stent-free treatment option for selected de novo small-vessel coronary disease. The device is designed to deliver localized anti-restenosis therapy without leaving a permanent metallic implant, supporting a vessel-preserving approach in narrow coronary vessels where restenosis risk and implant burden remain important clinical challenges.
Key Features
- Stent-free drug-coated balloon therapy
- Designed for selected de novo small-vessel coronary lesions
- Localized anti-restenosis drug delivery
- No permanent metallic implant left behind
- Supports vessel-preserving coronary intervention
- Designed to reduce long-term implant burden in small vessels
Stent-Free Coronary DCB for Bifurcation Lesions
An FDA Breakthrough Device-designated coronary drug-coated balloon catheter being developed as a stent-free treatment option for selected de novo coronary bifurcation lesions. The device is designed to deliver localized anti-restenosis therapy without leaving a permanent implant, helping preserve vessel anatomy and address procedural challenges associated with branch points and side-branch compromise.
Key Features
- Stent-free treatment approach for selected bifurcation lesions
- Designed to deliver localized anti-restenosis therapy
- No permanent metallic implant left behind
- Helps reduce side-branch jailing concerns
- Supports vessel-preserving treatment at coronary branch points
- Designed for complex de novo coronary anatomy
DLong’s Solution for CTEPH and Pulmonary Artery Stenosis
Plain Pulmonary Artery Balloon Dilatation Catheter
A non-drug-coated balloon catheter for pulmonary artery intervention in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary artery stenosis (PAS), including patients who are unsuitable for surgery or have residual or recurrent disease after pulmonary endarterectomy (PEA). Engineered for challenging pulmonary artery anatomy, the catheter is designed to support lesion access, controlled dilation, and repeated expansion cycles during pulmonary artery intervention.
Key Features
- Rapid-exchange catheter architecture
- Superior trackability for complex pulmonary artery anatomy
- Broad anatomical reach (diameter range: 1.0–10.0 mm, length up to 40 mm)
- Designed for durability during repeated expansion cycles
Paclitaxel-Coated Pulmonary Artery Balloon Catheter
An FDA Breakthrough Device-designated drug-coated balloon catheter designed for pulmonary artery stenosis treatment and pre-dilation-related interventional use. The catheter combines mechanical dilation with localized paclitaxel delivery, supporting immediate pharmacological intervention at the treated vessel segment.
Key Features
- Paclitaxel-coated balloon surface designed to inhibit cell proliferation
- Designed for rapid and efficient drug transfer to the vessel wall
- Combines mechanical dilation with localized drug delivery
- Developed for challenging pulmonary artery stenotic and obstructive lesions
DLong’s Solution for Vascular Intervention Simulation
Vascular Simulation & Training System
A procedure-oriented simulation system designed to support vascular device evaluation, physician education, product demonstration, and hands-on catheter-based intervention training.
Key Features
- Realistic vascular intervention simulation
- Guidewire navigation and injection technique training
- Balloon positioning and expansion practice
- Applications across pulmonary, coronary, neurovascular, and peripheral intervention
- Supports product development and clinical adoption
